a clinical-stage biopharmaceutical company
Industry Biotechnology
A.I.dvisor tells us that APRE and MBRX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APRE and MBRX's prices will move in lockstep.
Ticker / NAME | Correlation To APRE | 1D Price Change % | ||
---|---|---|---|---|
APRE | 100% | -2.88% | ||
MBRX - APRE | 26% Poorly correlated | -3.14% | ||
ONVO - APRE | 23% Poorly correlated | -3.09% | ||
CELU - APRE | 21% Poorly correlated | -7.14% | ||
RPRX - APRE | 20% Poorly correlated | -0.52% | ||
DTIL - APRE | 20% Poorly correlated | -4.41% | ||
More |